The US Food and Drug Administration has approved Takeda’s oveporexton, an oral orexin receptor 2 (OX2R)-selective agonist, for the treatment of narcolepsy type 1 (NT1) in adults.
Marketted as Orzeyful, the therapeutic is considered the first medicine approved for NT1 as a unified disorder, addressing the condition’s full symptom range, and the first to work by directly targeting the loss of orexin signaling that causes the disease.
The approval was based on 2 randomized, double-blind, placebo-controlled 12-week studies, FirstLight (NCT06470828) and RadiantLight (NCT06505031), enrolling a combined 273 adults with NT1.
Across both trials, oveporexton at the 2 mg dose met its primary endpoint, showing statistically significant improvement in the ability to stay awake during the day as measured by the Maintenance Wakefulness Test, relative to placebo.
Julie Flygare, president and CEO at Project Sleep, said, “This is a historic moment for the narcolepsy community. The approval gives new hope to people living with type 1 narcolepsy, like myself, and marks the beginning of a new era of orexin innovation.”
The FDA has also granted Regenerative Medicine Advanced Therapy (RMAT) designation to sasineprocel (ANPD001), Aspen Neuroscience’s lead investigational cell therapy for Parkinson disease (PD).
The designation provides increased guidance and expedited development support, including potential eligibility for priority review and accelerated approval.
Aspen Neuroscience is currently evaluating sasineprocel in an ongoing phase 1/2a ASPIRO trial (NCT06344026), an open-label, first-in-human study in patients with Parkinson’s disease aged 50 to 70 years.
Damien McDevitt, PhD, president and chief executive officer of Aspen Neuroscience, said, “This significant milestone highlights the transformative nature of sasineprocel as a potentially disease-modifying therapy for patients facing a serious disease with substantial unmet medical need.”
They might change the way we approach neurological disorders, potentially leading to more targeted and effective treatments.
It is a new approach.
As the FDA continues to support innovative therapies, people with narcolepsy type 1 (NT1) and Parkinson disease (PD) may benefit from these new treatments.
Researchers are working to develop more therapies.
The FDA approval of oveporexton and the RMAT designation for sasineprocel demonstrate the progress being made in the field of neurological disorders.
Takeda’s oveporexton is a significant development.
The company is committed to helping people with narcolepsy type 1 (NT1).
According to the filing, Aspen Neuroscience is also committed to developing new therapies for Parkinson disease (PD).
The report highlights the importance of continued research and development in the field of neurological disorders.
Journalists on the scene noted the significance of the FDA approval and the RMAT designation.
It marks a new era.
The outlet reported that the FDA is working to support innovative therapies.
Reporters noted that the approval of oveporexton and the RMAT designation for sasineprocel are significant milestones.
The care planning for people with neurological disorders is key.
They are making progress.
The researchers are working to develop more effective treatments.
It is a complex process.
The FDA is supporting innovative therapies.
The company is working to help people with narcolepsy type 1 (NT1) and Parkinson disease (PD).